Abstract / Summary
Background: To investigate the potential therapeutic benefits of autoimmune antibody detection in individuals suffering from chronic hepatitis B.
Methods: In the observation group, 102 patients with chronic hepatitis B who were admitted between March 2022 and March 2025 were included. Additionally, the control group consisted of 102 healthy people who were examined throughout the same time period. The two groups' autoimmune antibodies were identified, and patients in the observation group with either positive or negative autoimmune antibodies were compared in terms of liver function, liver fibrosis markers, and cytokine levels.
Results: The total positive rate of autoimmune antibodies in the observation group was 26.47%, whereas it was 3.92% in the control group (P<0.05). Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels were noticeably greater in patients in the observation group with positive autoimmune antibodies than in those with negative antibodies. However, the albumin (ALB) and total protein (TP) levels were much lower in these patients than in patients with negative antibodies. A statistically significant difference was observed (P< 0.05). The levels of type III procollagen (PCIII), hyaluronidase (HA), and laminin (LN) were significantly (P<0.05) greater in individuals with positive autoimmune antibodies than in those with negative antibodies. Patients with positive autoimmune antibodies had considerably higher levels of interleukin-4 (IL-4), interleukin-10 (IL-10), and interleukin-6 (IL-6) than patients with negative antibodies. Patients who were negative for antibodies had significantly higher levels of interferon-y (IFN-y) (P<0.05).
Conclusions: Autoimmune antibodies, which influence liver fibrosis indicators and related cytokines, are present in patients with chronic hepatitis B. The identification of autoimmune antibodies in chronic hepatitis B patients can serve as a guide for evaluating illness and determining patient prognosis.